A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder

作者：Milak M S^*; Proper C J; Mulhern S T; Parter A L; Kegeles L S; Ogden R T; Mao X; Rodriguez C I; Oquendo M A; Suckow R F; Cooper T B; Keilp J G; Shungu D C; Mann J J

来源：Molecular Psychiatry, 2016, 21(3): 320-327.

DOI：10.1038/mp.2015.83

The N-methyl-D-aspartate receptor antagonist ketamine can improve major depressive disorder (MDD) within hours. To evaluate the putative role of glutamatergic and GABAergic systems in ketamine's antidepressant action, medial prefrontal cortical (mPFC) levels of glutamate+glutamine (Glx) and gamma-aminobutyric acid (GABA) were measured before, during, and after ketamine administration using proton magnetic resonance spectroscopy. Ketamine (0.5?mg kg(-1) intravenously) was administered to 11 depressed patients with MDD. Glx and GABA mPFC responses were measured as ratios relative to unsuppressed voxel tissue water (W) successfully in 8/11 patients. Ten of 11 patients remitted (50% reduction in 24 item Hamilton Depression Rating Scale and total score ?10) within 230? min of commencing ketamine. mPFC Glx/W and GABA/W peaked at 37.8%+/- 7.5% and 38.0%+/- 9.1% above baseline in similar to 26?min. Mean areas under the curve for Glx/W (P=0.025) and GABA/W (P=0.005) increased and correlated (r=0.796; P=0.018). Clinical improvement correlated with 90-min norketamine concentration (df=6, r=-0.78, P=0.023), but no other measures.

• 出版日期2016-3